6-(5-fluoropyridin-3-yl)pyrimidine-4-carboxylic acid | 1097254-32-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(5-fluoropyridin-3-yl)pyrimidine-4-carboxylic acid
• CAS: 1097254-32-4
• 化学式: C₁₀H₆FN₃O₂
• 分子量: 219.175
• InChiKey: YFSZQELSFYRGSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
  申请人：Chen Weirong

  公开号：US20090036419A1

  公开（公告）日：2009-02-05

  The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

  本发明提供了作为Raf蛋白激酶抑制剂有用的化合物。本发明还提供了这些化合物的组合物，以及治疗Raf介导疾病的方法。
• PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
  申请人：Sunesis Pharmaceuticals, Inc.

  公开号：EP2167489B1

  公开（公告）日：2017-05-03
• CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：CHDI, Inc.

  公开号：EP2331095A1

  公开（公告）日：2011-06-15
• THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS
  申请人：Sunesis Pharmaceuticals, Inc.

  公开号：EP3231798B1

  公开（公告）日：2019-10-09
• KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Courtney Stephen Martin

  公开号：US20140329795A1

  公开（公告）日：2014-11-06

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.